

Bogdan Mitran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1399432/publications.pdf>

Version: 2024-02-01

48
papers

1,146
citations

331670

21
h-index

434195

31
g-index

48
all docs

48
docs citations

48
times ranked

1133
citing authors

#	ARTICLE	IF	CITATIONS
1	Affibody-mediated PET imaging of HER3 expression in malignant tumours. <i>Scientific Reports</i> , 2015, 5, 15226.	3.3	56
2	The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a ⁶⁸ Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin. <i>Molecules</i> , 2014, 19, 10455-10472.	3.8	55
3	PET imaging of epidermal growth factor receptor expression in tumours using ⁸⁹ Zr-labelled ZEGFR:2377 affibody molecules. <i>International Journal of Oncology</i> , 2016, 48, 1325-1332.	3.3	50
4	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1092-1098.	5.0	48
5	The effect of macrocyclic chelators on the targeting properties of the ⁶⁸ Ga-labeled gastrin releasing peptide receptor antagonist PEG 2-RM26. <i>Nuclear Medicine and Biology</i> , 2015, 42, 446-454.	0.6	46
6	Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting. <i>Journal of Nuclear Medicine</i> , 2016, 57, 431-436.	5.0	46
7	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. <i>Journal of Controlled Release</i> , 2018, 288, 84-95.	9.9	40
8	Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. <i>Molecular Pharmaceutics</i> , 2019, 16, 995-1008.	4.6	35
9	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. <i>Molecular Pharmaceutics</i> , 2016, 13, 1668-1678.	4.6	33
10	Cyclic versus Noncyclic Chelating Scaffold for ⁸⁹ Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. <i>Molecular Pharmaceutics</i> , 2018, 15, 175-185.	4.6	31
11	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. <i>Molecular Pharmaceutics</i> , 2016, 13, 3676-3687.	4.6	30
12	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-11.	0.8	30
13	Trastuzumab cotreatment improves survival of mice with PC prostate cancer xenografts treated with the GRPR antagonist ¹⁷⁷ Lu-DOTAGA-PEG ₂ -RM26. <i>International Journal of Cancer</i> , 2019, 145, 3347-3358.	5.1	30
14	Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. <i>International Journal of Oncology</i> , 2016, 48, 2124-2134.	3.3	29
15	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. <i>Scientific Reports</i> , 2017, 7, 5961.	3.3	29
16	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. <i>Journal of Nuclear Medicine</i> , 2018, 59, 93-99.	5.0	29
17	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with ^{99m} Tc using a peptide-based cysteine-containing chelator. <i>International Journal of Oncology</i> , 2016, 49, 2285-2293.	3.3	27
18	High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-10.	0.8	27

#	ARTICLE	IF	CITATIONS
19	Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. <i>Cancers</i> , 2019, 11, 1371.	3.7	26
20	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. <i>Theranostics</i> , 2018, 8, 4462-4476.	10.0	25
21	Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: Development of an optimized conjugation protocol and ¹⁷⁷ Lu labeling. <i>Nuclear Medicine and Biology</i> , 2017, 54, 1-9.	0.6	24
22	Evaluation of ^{99m} Tc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. <i>Amino Acids</i> , 2015, 47, 303-315.	2.7	22
23	Preclinical Evaluation of [⁶⁸ Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. <i>Cells</i> , 2018, 7, 141.	4.1	21
24	Selection of the optimal macrocyclic chelators for labeling with ¹¹¹ In and ⁶⁸ Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 140, 109-120.	4.3	21
25	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of ⁶⁸ Ga-Labeled Tracers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1080.	4.1	21
26	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 134, 37-48.	4.3	21
27	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. <i>Scientific Reports</i> , 2017, 7, 43118.	3.3	20
28	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. <i>Biomaterials</i> , 2019, 203, 73-85.	11.4	19
29	Comparison of tumor targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. <i>International Journal of Oncology</i> , 2019, 54, 1209-1220.	3.3	19
30	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer – Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. <i>Pharmaceutics</i> , 2020, 12, 614.	4.5	19
31	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. <i>Scientific Reports</i> , 2019, 9, 655.	3.3	18
32	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. <i>Scientific Reports</i> , 2017, 7, 14780.	3.3	17
33	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. <i>Pharmaceutics</i> , 2019, 11, 358.	4.5	17
34	Synthesis of ¹¹ C-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [¹¹ C]CO. <i>ChemistryOpen</i> , 2016, 5, 566-573.	1.9	16
35	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of ^{99m} Tc-labeled anti-EGFR affibody molecules. <i>Amino Acids</i> , 2018, 50, 981-994.	2.7	16
36	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with ¹¹¹ In and ⁶⁸ Ga. <i>Molecular Pharmaceutics</i> , 2018, 15, 2674-2683.	4.6	15

#	ARTICLE	IF	CITATIONS
37	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. <i>Scientific Reports</i> , 2019, 9, 17086.	3.3	14
38	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. <i>Scientific Reports</i> , 2019, 9, 14907.	3.3	14
39	Increase in negative charge of ⁶⁸ Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. <i>Scientific Reports</i> , 2019, 9, 17710.	3.3	14
40	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. <i>Bioconjugate Chemistry</i> , 2016, 27, 2678-2688.	3.6	13
41	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. <i>Scientific Reports</i> , 2018, 8, 9643.	3.3	11
42	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. <i>International Journal of Oncology</i> , 2017, 51, 1765-1774.	3.3	10
43	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1972.	4.1	9
44	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. <i>Current Medicinal Chemistry</i> , 2020, 27, 7090-7111.	2.4	9
45	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. <i>Scientific Reports</i> , 2019, 9, 6779.	3.3	8
46	Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart. <i>Pharmaceutics</i> , 2019, 11, 380.	4.5	6
47	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. <i>Molecules</i> , 2020, 25, 5993.	3.8	6
48	Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377. <i>Oncology Reports</i> , 2018, 41, 534-542.	2.6	4